Biofourmis

By Dave Muoio 03:12 pm November 20, 2019
Sanofi is merging its real-world data platform with New York startup Aetion’s similar evidence platform to augment its treatment development and deployment efforts, the companies announced today. Sanofi’s DARWIN platform will provide a substantial body of de-identified patient data, which the Aetion Evidence Platform will analyze those information for insights on drug effectiveness, safety and...
By Laura Lovett 11:49 am November 18, 2019
This morning Biofourmis, maker of an artificial intelligence-enabled monitoring and decision support platform, announced its plans to acquire Zürich, Switzerland-based wearable biosensor company Biovotion. The terms of the deal are not disclosed; however, we do know the deal is made up of a combination of cash and equity.  The acquisition will include Biovotion’s clinical grade-wearable...
By Laura Lovett 10:23 am May 21, 2019
This morning, artificial-intelligence-enabled monitoring and decision support platform Biofourmis announced a $35 million Series B raise. The round was led by Sequoia India and MassMutual Ventures with participation from EDBI, Jianke and existing investors Openspace Ventures, Aviva Ventures and SGInnovate.  The funding announcement coincided with the news that the Singaporean company will be...
By Dave Muoio 01:37 pm May 2, 2019
The FDA has granted 510(k) clearance to Biofourmis’ RhythmAnalytics, a cloud-based software product that uses deep learning to read and interpret cardiac arrhythmias. According to a statement from the company and the FDA’s clearance letter, RhythmAnalytics collects single-lead ECG data from a range of FDA-cleared devices, and from these scan for more than 15 types of cardiac arrhythmias,...